Active Biotech has Confirmed Localization of ANYARA in Cancer Patients

In an ongoing clinical Phase I study, specific tumour localization of Active Biotech AB's candidate drug ANYARA, has been objectively confirmed.

Using Positron Emission Tomography, PET, and radioactively labelled ANYARA, drug concentrations in tumour and normal tissues of individual patients have been measured for the first time, demonstrating that ANYARA localizes to tumours that express the target antigen 5T4. The study is ongoing at Paterson Institute for Cancer Research and at Christie Hospital, Manchester, UK and the first results from this study will be presented at the NCRI, National Cancer Research Institute, conference held in Birmingham, UK on October 2-5.

Another Phase I clinical dose escalation trial with ANYARA is ongoing at the Fox Chase Cancer Centre in Philadelphia, USA, at the Norwegian Radium Hospital in Oslo, Norway and at Christie Hospital, Manchester, UK.

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex for RA.

For further information please contact:

Sven Andréasson,

President & CEO,

Tel: +46 46 19 20 49

Email: sven.andreasson@activebiotech.com

Or visit: http://www.activebiotech.com